Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis.
Fiche publication
Date publication
février 2024
Journal
International journal of cosmetic science
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GALZI Jean-Luc
Tous les auteurs :
Frossard N, Coïc A, Saguet T, Coïc A, Himbert F, Do QT, Galzi JL, Suehs C, Guillaumet G, Bonnet P, Bernard P
Lien Pubmed
Résumé
Atopic dermatitis has a marked economic impact and affects the quality of life. A cosmetic compound with an innovative strategy is proposed here as a small chemical neutraligand, GPN279 (previously identified as a theophylline derivative), that binds and potently neutralizes the TARC/CCL17 chemokine, activating the Th2 cell-expressed CCR4 receptor.
Mots clés
CCL17 chemokine neutraligand, atopic dermatitis, claim substantiation, skin barrier, skin physiology/structure
Référence
Int J Cosmet Sci. 2024 02 7;: